In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on uniQure NV (QURE – Research Report), with a price target of $175. The company’s shares closed yesterday at $58.51.
“We believe uniQure, a 2019, could be en route to $5-10bn valuation, based on support in the coming year from what could be a best-in-class, breakthrough Huntington’s disease (HD) franchise. HD is a universally fatal monogenic (autosomal dominant) disease that usually starts between ages 30 and 50, followed by movement, cognitive, and psychiatric impairment. Death typically follows 10 to 30 years after diagnosis. In 2H19, uniQure is expected to make AAV5-based gene therapy (GT), AMT-130, the first 1-time GT to enter the clinic for HD. AMT-130 utilizes uniQure’s miQURE silencing technology to inhibit the production of the mutant huntingtin protein (mHTT).”
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 17.0% and a 49.5% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Iovance Biotherapeutics Inc, and Logicbio Therapeutics Inc.
Currently, the analyst consensus on uniQure NV is a Strong Buy with an average price target of $78.67, which is a 34.5% upside from current levels. In a report issued on May 13, H.C. Wainwright also maintained a Buy rating on the stock with a $73 price target.
Based on uniQure NV’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $27.77 million. In comparison, last year the company had a GAAP net loss of $18.79 million.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.